title: Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
abstract: Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.
authors.affiliation: Division of Infectious Diseases, Santa Clara Valley Medical Center, 751 South Bascom Ave., San Jose, CA 95128-2699, USA. clemons@cimr.org
authors.forename: Jackie K
authors.initials: JK
authors.lastname: Imai
authors.forename: Gaurav
authors.initials: G
authors.lastname: Singh
authors.forename: Karl V
authors.initials: KV
authors.lastname: Clemons
authors.forename: David A
authors.initials: DA
authors.lastname: Stevens
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus; D020314:Central Nervous System Fungal Infections / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D051379:Mice; D013534:Survival; D016019:Survival Analysis; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole; D000666:Amphotericin B